Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Published Online: 2023-01-?
Journal: The Lancet•Publisher: Elsevier BV
Authors: Anton Egorov•Binghe Xu•Chiun-Sheng Huang•Erika Hamilton•Giampaolo Bianchini•Giuseppe Curigliano•Hiroji Iwata•Jan-Willem Henning•Javier Cortés•Jean-Sebastien Frenel•Jillian Cathcart•Joanne Wing Yan Chiu•José Manuel Perez-Garcia•Junji Tsurutani•Roberto Hegg•Sara A Hurvitz•Seock-Ah Im•Sevilay Altintas•Shahid Ashfaque•Sherene Loi•Silvia Antolin•Srinivasan Madhusudan•Sung-Bae Kim•Vanessa Petry•Vinod Ganju•Wei Li•Wei-Pang Chung•William Jacot•Winnie Yeo•Yali Liu
